Yousif Capital Management LLC Lowers Position in Thermo Fisher Scientific Inc. $TMO

Yousif Capital Management LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,900 shares of the medical research company’s stock after selling 773 shares during the period. Yousif Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $16,583,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. CBIZ Investment Advisory Services LLC raised its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after buying an additional 33 shares in the last quarter. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $37,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $524.95 on Monday. The firm has a market cap of $198.23 billion, a P/E ratio of 30.36, a P/E/G ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The business’s 50 day moving average price is $488.68 and its 200-day moving average price is $447.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research report on Wednesday. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Raymond James Financial restated an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $593.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.